Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Exclusive CEO Interview Karim Rayani, Marvel Discovery Corp.

Earlier this month copper & nickel hit all-time highs and gold came within 1% of an ATH. increased its 3 & 6 month gold targets to & . Still, many metals/mining juniors are well below their 52-week highs. That could change at any time. In commodity bull markets, investors...
Peter Epstein | March 18, 2022 |

Rising to Meet the Green Revolution

Q&A with Max Resource Corp Max Resource Corp ( TSX-V: MXR ) is a copper and precious metals exploration company focused on projects in Colombia and Peru. In this in-depth Q&A, Max’s executive team shares investment highlights and key moments in 2021&CloseC...
Featured Submission | October 20, 2021 |

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...
Streetwise Reports | May 28, 2020 |